Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 20

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Oct 26, 2020; 8(20): 4793-4806
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4793

Table 2 Utilities used in the base case analysis

Health state	Utility (SE)	Source
Sweden
Midgut-NET progression-free survival	0.79 (0.01)	Real world evidence¹
Midgut-NET post-progression survival	0.74 (0.01)	ERASMUS study²
P-NET progression-free survival	0.80 (0.01)	ERASMUS study²
P-NET post-progression survival	0.79 (0.02)	ERASMUS study²
Norway
Midgut-NET progression-free survival (Lutathera)	0.75 (0.01)	NETTER-1[13]
Midgut-NET post-progression survival	0.74 (0.01)	ERASMUS study²
P-NET progression-free survival	0.80 (0.01)	ERASMUS study²
P-NET post-progression survival	0.79 (0.02)	ERASMUS study²

¹Real world study conducted at Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom (AAA, data on file).

²AAA data on file. Midgut-NET: Midgut neuroendocrine tumor; P-NET: Pancreatic neuroendocrine tumor; SE: Standard error.

Citation: Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (¹⁷⁷Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806
URL: https://www.wjgnet.com/2307-8960/full/v8/i20/4793.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i20.4793

Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (¹⁷⁷Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806 [PMID: 33195647 DOI: 10.12998/wjcc.v8.i20.4793]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.